. | Black . | White . |
---|---|---|
n | 467 (26) | 1,339 (74) |
Female sex (%) | 52 | 41 |
Age at time of diagnosis (%) | ||
<45 years | 29 | 14 |
45–64 years | 62 | 54 |
>65 years | 9 | 32 |
Mean A1C level (%) | % missing: 14 | % missing: 13 |
9.8 ± 2.4 | 8.9 ± 2.1 | |
BMI (kg/m2) | % missing: 28 | % missing: 29 |
Underweight to normal (%) | 11 | 9 |
Overweight | 31 | 29 |
Obese | 58 | 62 |
Any hospitalization (%) | 9 | 12 |
Mean systolic blood pressure >130 mmHg (%) | % missing: 1 | % missing: 2 |
61 | 67 | |
Mean total cholesterol >5.18 mmol/l or >200 mg/dl (%) | % missing: 34 | % missing: 31 |
74 | 72 | |
Medication use at initiation of therapy | ||
Glyburide | 83 | 78 |
Metformin HCl | 13 | 14 |
Glipizide | 3 | 6 |
All other (acarbose, rosiglitazone, tolazamide, tolbutamide) | 1 | 2 |
>1 oral hypoglycemic medication | 3 | 2 |
. | Black . | White . |
---|---|---|
n | 467 (26) | 1,339 (74) |
Female sex (%) | 52 | 41 |
Age at time of diagnosis (%) | ||
<45 years | 29 | 14 |
45–64 years | 62 | 54 |
>65 years | 9 | 32 |
Mean A1C level (%) | % missing: 14 | % missing: 13 |
9.8 ± 2.4 | 8.9 ± 2.1 | |
BMI (kg/m2) | % missing: 28 | % missing: 29 |
Underweight to normal (%) | 11 | 9 |
Overweight | 31 | 29 |
Obese | 58 | 62 |
Any hospitalization (%) | 9 | 12 |
Mean systolic blood pressure >130 mmHg (%) | % missing: 1 | % missing: 2 |
61 | 67 | |
Mean total cholesterol >5.18 mmol/l or >200 mg/dl (%) | % missing: 34 | % missing: 31 |
74 | 72 | |
Medication use at initiation of therapy | ||
Glyburide | 83 | 78 |
Metformin HCl | 13 | 14 |
Glipizide | 3 | 6 |
All other (acarbose, rosiglitazone, tolazamide, tolbutamide) | 1 | 2 |
>1 oral hypoglycemic medication | 3 | 2 |
Data are n (%), %, or means ± SD. Bold indicates values statistically significant at the P < 0.05 level.